Tk. Makris et al., Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol, AM J HYPERT, 13(7), 2000, pp. 783-788
Essential hypertension is often accompanied by abnormalities of the coagula
tion/fibrinolytic system, predisposing to a procoagulant state. The aim of
the present study was to compare the effects of atenolol (beta(1)-blocker a
gent) and irbesartan (angiotensin II type 1 receptor antagonist) on plasma
levels of hemostatic/fibrinolytic and endothelial function markers in a coh
ort of previously untreated hypertensives. Fifty-four patients were randoml
y assigned to atenolol 25 to 150 mg (26 patients) or irbesartan 75 to 300 m
g (28 patients). The plasma levels of plasminogen activator inhibitor-1 ant
igen, thrombomodulin, tissue factor pathway inhibitor antigen, fibrinogen,
and factor XII were determined before and after 6 months of therapy. Age, g
ender distribution, body mass index, lipid profile, and baseline values of
the measured markers were similar in both groups. Baseline values for systo
lic and diastolic blood pressure, as well as the reduction after treatment,
were not significantly different between the two groups. Treatment with ir
besartan was associated with a significant decrease in the levels of all th
e parameters. Similar findings were observed in the atenolol group, except
for factor XII and tissue factor pathway inhibitor levels, which were not s
ignificantly decreased in this group. The reduction, however, of fibrinogen
, plasminogen activator inhibitor-1, and thrombomodulin was significantly g
reater in the irbesartan than in the atenolol group. In conclusion, the res
ults indicated that, despite an equally controlled blood pressure, 6-month
therapy with irbesartan was associated with a more favorable modification o
f hemostatic/fibrinolytic status than atenolol. (C) 2000 American Journal o
f Hypertension, Ltd.